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AbstrAct:
A major endeavour in cancer chemotherapy is to develop agents that specifically 
target a biomolecule of interest. There are two main classes of targeting 
agents: small molecules and biologics. Among biologics (e.g.: antibodies), 
DNA, RNA but also peptide aptamers are relatively recent agents. Peptide 
aptamers are seldom described but represent attractive agents that can inhibit 
a growing panel of oncotargets including Heat Shock Proteins. Potential pitfalls 
and coming challenges towards successful clinical trials are presented such 
as optimizing the delivery of peptide aptamers thanks to Nanotechnology.
Rational drug design is the quest, launched by 
Paul Ehrlich about a century ago, for designing a ‘magic 
bullet’: a targeting agent that specifically interacts with, 
and mostly inhibits, a biomolecule of interest. Essentially, 
this biomolecule is an intracellular or membrane-bound 
protein identified as contributing to a disease state. The 
choice of the protein to be targeted is constrained by our 
ability obtain highly specific, bioactive ligands. Usually, 
for small molecules, a requirement is the presence of a 
pocket (e.g.: the ATP-binding cavity of protein kinases) 
where the targeting agent can fit snugly and establish the 
multiple  low-energy  interactions  in  3  dimensions  that 
confers its (high) affinity and specificity.
Within the last 10 years[1], a number of such 
targeting agents have been discovered by screening or 
rational design. They fall in 2 classes: small molecules and 
biologics. The former are developed by (pharmaceutical) 
chemists,  with  imatinib  as  an  archetype.  The  latter 
originate from molecular biologists and are typically 
represented  by  monoclonal  antibodies  (mAbs)  such  as 
trastuzumab or cetuximab. Due to their size (molecular 
weight <500Da[2]), small molecules are relatively easy 
to  synthesize,  can  diffuse  well  (including  through  the 
membrane bilayer) and are generally orally available[3]. 
On  the  other  hand,  mAbs  are  large  (~150kDa[4,  5]) 
and  complex  molecules[6]  that  are  delivered  intra-
tumorally  or  intravenously[3].  To  reduce  the  immune 
response  they  inherently  trigger,  efforts  were  devoted 
to  design  new  generations  of  antibodies  switching 
from murine antibodies to: chimeric (~60% human, 
example:  Cetuximab[7]),  humanized  (~90%  human, 
e.g.:  Trastuzumab)  or  human  antibodies  (100%,  e.g.: 
Panitumumab). Up to now, biologics have in fact a higher 
rate of approval success rate (18% for chimeric and 24% 
humanized  monoclonal  antibodies)  than  new  chemical 
entities including small molecules (5%)[3, 8] especially 
in oncology[3]. 
A new tool: peptide AptAmers
Among biologics, aptamers (a word combining the 
Latin aptus ‘fitting’ with the Greek meros ‘part’[9]) are 
emerging as a new class of targeting agents. Aptamers 
(i.e.: DNA, RNA aptamers) but also peptide aptamers are 
indeed apt to specifically inhibit biomolecules of interest 
with high affinity[9-11]. 
Peptide aptamers consist of a short (~10-20 amino 
acids), conformationally constrained[12] variable random 
peptide sequence inserted into a scaffold protein (most 
often the bacterial protein thioredoxin A[12, 13]) as shown 
in figure 1. They can thus be considered as miniaturized, 
simplified antibodies[12, 13]. A unique feature of peptide 
aptamers relies in their doubly constrained target-binding 
loop[13], compared to other man-made biomolecules that 
consist of peptidic sequences fused terminally to a carrier Oncotarget 2011; 2:  557 - 561 558 www.impactjournals.com/oncotarget
protein.  Constrained  conformations[13-15]  require  less 
energy to bind the target of interest, resulting in peptide 
aptamers with high affinities and KD values in the 10 – 100 
nM range[10, 12]. Compared to monoclonal antibodies, 
DNA,  RNA  and  peptide  aptamers  are  relatively  small, 
weighting ~10-20kDa[16] with reduced immunogenicity 
compared to antibodies[9]. 
trAnslAtion to the clinics: of 
mice And men:
Of  the  ~108,400  recorded  clinical  trials  (http://
clinicaltrials.gov/, last access: the 8th of June 2011), ~5,500 
are involving targeted therapies, with ~1,700 in the field 
of oncology. Among these, there are ~500 trials assessing 
peptides but only 3 studies concerning aptamers (none 
with peptide aptamers). There are at least 2 interesting 
approaches to be enlightened. One is the success of 
Pegaptanib sodium (Macugen, Eyetech Pharmaceuticals/
Pfizer), the first FDA-approved aptamer (December 2004) 
for use in humans. As with other types of agents, it took 
about  a  decade  of  preclinical  development  to  improve 
and characterize its biological effects[17]. Nevertheless, 
this  anti-VEGF  pegylated  RNA  aptamer  developed 
for  the  treatment  of  neovascular  age-related  macular 
degeneration  is  now  involved  in  ~50  trials.  Another 
interesting example includes AS1411 (4 clinical trials) for 
the study of Acute Myeloid Leukemia (2 clinical trials), 
Renal  Cell  Carcinoma  (1  clinical  trial)  and  advanced 
tumors  (1  clinical  trial).  This  DNA  aptamer  targeting 
nucleolin induces apoptosis and may be combined with 
cytarabine to obtain a synergistic effect. It is the first-in-
class DNA aptamer anticancer agent, and is currently in 
phase II clinical trials including solid tumours[18]. 
More  recently  developed,  peptide  aptamers  are 
to date tested in preclinical models only. In the context 
of oncology, in vitro and/or in vivo data indicate that 
peptide aptamers are able to inhibit a growing panel of 
oncotargets including: the human papillomavirus HPV16 
E6 oncoprotein[19] in 2000, ErbB2 receptor[20], mutant 
p53[21], but also HSP70[22] and HSP27[23] within these 
last months. So what are the foreseen barriers towards 
successful clinical trials?
reaching the tumor
To date, peptide aptamers target the cancer cells via 
different means. The two most frequent delivery options 
are liposome-like chariots and protein transduction 
domains (PTDs). Potential issues of the former approach 
might be related to toxicity and stability. Concerning the 
later, the most widely used PTD, derived from HIV-TAT 
protein, is a positively charged sequence that represents 
an interesting approach. However, it might affect protein 
structure. Far from trivial, delivering the targeting agent 
specifically to the desired site of action will more than 
probably benefit from nanotechnology. Several ongoing 
clinical options exist. They include drug delivery systems 
composed of: lipid nanoparticles, albumin-based, 
micelles,  polymer-based  or  gold  nanoparticles[9]  that 
should be investigated for peptide aptamers. 
dose calculations
Different from organic small molecules by nature, 
dose calculations for biologics nevertheless remain almost 
exclusively  traditional[24]  even  though  they  exhibit 
non-linear dose-response curves[6]. As targeting agents 
are  often  combined  with  cytotoxics  (e.g.:  doxorubicin, 
cisplatin  or  taxol),  drug  combinations  need  careful 
evaluation. Also, the design of clinical trials for targeting 
agents should be revisited accordingly[25].
early detection
Obviously,  the  earlier  the  disease  is  detected,  the 
greater the chances of curing it. Efforts should be devoted 
to improve current detection limits. Also, it is necessary 
to develop and validate appropriate biomarkers for cancer 
diagnosis as well as treatment follow-up[26]. Interestingly, 
aptamers can be functionalized onto sensing schemes for 
biodetection[9] with the emerging ‘aptasensors’[27].
Patient selection: when one treatment does not fit 
all
Related to early detection is the identification of the 
figure 1: oncotargets of peptide aptamers. The typical 
structure of a peptide aptamer is composed of a constant 
scaffold (in blue, e. g. : the bacterial protein thioredoxin A) with 
an inserted short variable random region (in red). A panel of 
oncotargets inhibited by peptide aptamers is provided.
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right panel of patients. Cancer is known to be a highly 
heterogeneous disease. For instance, the EGFR pathway 
is  disrupted  in  fewer  than  15%  of  patients  with  lung 
cancer[28]. One of the 4 EGFR family member, HER2, 
is overexpressed in ~30% of breast cancers[6, 29]. Thus, 
averaging the response of a few responders in an overall 
non-responding  group  would  be  cancelled  out  and  the 
development  of  companion  diagnostics  to  eventually 
identify suitable patients is mandatory. 
side effects: evolution for every one
Since “Nothing makes sense in medicine except in 
the light of biology”[30] and also that “Nothing in biology 
makes sense except in the light of evolution”[30], it may 
prove useful to get insights from an evolutionary process 
that shaped us over a couple of billions of years. The quest 
for new agents have led to some disastrous clinical trials 
like CAST and SWORD in cardiology[31]. Some of the 
lessons learned are that searching for druggable portions 
of different types of ion channels (e.g.: sodium, potassium) 
may lead to a common –well conserved- protein domain 
(e.g.:  the  pore-forming  modules[32])  that  is  shared  by 
those different types of channels[33], potentially leading 
to  undesired  effects  and  complex  cardiac  patterns[31], 
sometimes lethal. In cancer, a similar pitfall was recently 
noticed  when  assessing  the  selectivity  of  erlotinib 
hydrochloride,  gefitinib  and  imatinib  for  instance[29]. 
Targeting ATP-pockets is actually a very common trend 
in rational drug design since these pockets exhibit high 
druggability indexes and may be seen as a bias from the 
concept  of  druggability.  Therefore,  when  intending  to 
design a specific inhibitor, one should also evaluate sets of 
related targets which contain similar pockets. For protein 
kinases for instance, the human kinome space was found 
to consist of 518 kinases[34]. As a general guideline, a 
threshold of 60% sequence identity was determined for 
the ATP-pocket that differentiated between binding sites 
of related kinases versus variations in the binding sites 
of the same kinase[35]. This indicates that kinases with a 
sequence identity >60% have a high probability of being 
inhibited by the same compounds[35]. Peptide aptamers 
were  in  fact  developed  to  circumvent  the  requirement 
of targeting pockets and to address other types of target 
sites, non-druggable by small molecules. They can inhibit 
protein  function  via  the  disruption  of  protein-protein 
interactions or a number of other mechanisms[36]. In the 
context of protein kinases, inhibitory peptide aptamers 
would be expected to be more specific than their small 
molecules inhibitors, thereby reducing side-effects related 
to off-targets inhibition.
concluding remArks
The  attrition  rate  in  clinical  trials  remains  high, 
especially  in  cancer[8].  One  major  reason  probably 
relies in the intrinsic heterogeneity of tumors that 
harbour several mutations[37, 38]. Therefore, instead of 
heading for the design of the magic bullet, one may in 
fact want to broaden the spectrum of targets, and move 
towards polypharmacology as interaction networks play 
an increasing role in our current understanding of drug 
efficacy and side effects[39-41]. It was indeed found for 
instance that one of the archetypes of targeted therapy, 
imatinib,  inhibits  other  proteins  as  well  and  is  thus  in 
fact not perfectly specific[39]. Alternatives to ‘dirty’ or 
promiscuous drugs intended to target and inhibit a set of 
pathways disrupted in cancer include targeting a molecular 
chaperone,  ideally  an  inducible  heat  shock  protein[22, 
23, 42]. The rational is that cancer cells, because they 
must  extensively  rewire  their  metabolic  and  signalling 
networks, need for their survival an abundant content of 
chaperones like the inducible HSP70 or HSP27 that are no 
or hardly expressed in normal cells. This general cancer 
cells’ addiction to heat shock proteins make the recently 
described  HSP70  and  HSP27  peptide  aptamers  all  the 
more interesting as sensitizing agents in cancer therapy. 
However, the use of peptide aptamers as targeting agents 
in cancer therapy need to be carefully validated since the 
existing data is only preclinical.
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